Combination atypical antipsychotics in adolescents or adults with bipolar disorder with psychotic features a review of clinical and cost-effectiveness and guidelines

Bipolar disorder is a mental condition characterized by episodic mood swings between euphoric or irritable mania and hopeless depression which can affect social activities, functioning, and relationships. Episodes are typically followed by symptom-free periods referred to as euthymia. According to a...

Full description

Bibliographic Details
Corporate Author: Canadian Agency for Drugs and Technologies in Health
Format: eBook
Language:English
Published: Ottawa Canadian Agency for Drugs and Technologies in Health 2016, 06 September 2016
Series:Rapid response report: summary with critical appraisal
Subjects:
Online Access:
Collection: National Center for Biotechnology Information - Collection details see MPG.ReNa
LEADER 03714nam a2200277 u 4500
001 EB001840304
003 EBX01000000000000001004293
005 00000000000000.0
007 tu|||||||||||||||||||||
008 180702 r ||| eng
245 0 0 |a Combination atypical antipsychotics in adolescents or adults with bipolar disorder with psychotic features  |h Elektronische Ressource  |b a review of clinical and cost-effectiveness and guidelines 
260 |a Ottawa  |b Canadian Agency for Drugs and Technologies in Health  |c 2016, 06 September 2016 
300 |a 1 PDF file (6 pages)  |b illustrations 
653 |a Adult 
653 |a Antipsychotic Agents 
653 |a Adolescent 
653 |a Bipolar Disorder / drug therapy 
710 2 |a Canadian Agency for Drugs and Technologies in Health 
041 0 7 |a eng  |2 ISO 639-2 
989 |b NCBI  |a National Center for Biotechnology Information 
490 0 |a Rapid response report: summary with critical appraisal 
856 4 0 |u https://www.ncbi.nlm.nih.gov/books/NBK395828  |3 Volltext  |n NLM Bookshelf Books  |3 Volltext 
082 0 |a 610 
520 |a Bipolar disorder is a mental condition characterized by episodic mood swings between euphoric or irritable mania and hopeless depression which can affect social activities, functioning, and relationships. Episodes are typically followed by symptom-free periods referred to as euthymia. According to a survey conducted in 2002, one percent (1%) of Canadians 15 years and older demonstrated symptoms satisfying the criteria for bipolar disorder in the previous 12 months. Multiple types of bipolar disorders exist such as bipolar I, bipolar II and are defined in the Diagnostic and Statistical Manual (5th edition; DSM-V) from the American Psychiatric Association. Symptoms associated with mania can include increased creativity and productivity; however, mania can also lead to immediate hospitalization or involuntary committal under the Mental Health Act. Symptoms associated with depression can lead to increased rates of suicide and suicide ideation.  
520 |a Atypical antipsychotics, such as aripiprazole, olanzapine, quetiapine, risperidone and ziprasidone can be prescribed as monotherapy or in combination with mood stabilizers and antidepressants, as well as other treatment options. Although combinations of atypical antipsychotics have been used for the treatment of other disorders, such as schizophrenia, the effectiveness of combination therapy in bipolar disorder is unclear. This Rapid Response report aims to review the clinical and cost-effectiveness of combination atypical antipsychotics in adolescents or adults with bipolar disorder with psychotic features. Guidelines associated with the use of combination atypical antipsychotics in adolescents or adults with bipolar disorder with psychotic features will also be examined 
520 |a Bipolar disorder with psychotic features refers to manic or depressive episodes including psychotic symptoms such as delusions or hallucinations. Psychotic features manifest in over 50% of manic episodes and are more common in the latter than in depressive episodes. Pharmacological treatment usually depends on the type of bipolar disorder (manic or depressive); however, the most common treatments include lithium and valproic acid. Antipsychotic medications are also used to treat bipolar disorder and can be classified as typical (first generation) or atypical (second generation). First generation antipsychotics mitigate bipolar disorder symptoms by antagonizing dopamine D2 receptors, while second generation antipsychotics have an affinity for serotonin 5-hydroxytryptamine receptors and adrenergic receptors in addition to being D2 receptor antagonists.